Poll Results

How will the addition of step therapy on Medicare Part B drugs impact biosimilars?

Increase use of biosimilars:  54.55%

No Change:  36.36%

Decrease biosimilar use:  9.09%

Will deeply discounted WAC prices (list price) for biosimilars and specialty generics influence uptake?

Yes: 28.6%

Some impact: 57.1%

No: 14.3%

What is your opinion on pharmacists being allowed to refuse to dispense a prescription for ethical reasons?

Agree: 12.5%

Agree, if they can find another reasonable option for the patient: 56.25%

Disagree: 25%

Indifferent: 6.25%

Do you feel that disclosing the list price of prescription drugs during DTC ads will decrease patient demand for certain products?

Yes: 14.3%

No: 85.7%

Are pharmacists’ licenses at risk when dispensing medical marijuana, a DEA Schedule I substance?

Yes: 66.7%

No: 33.3%

Which of these do you expect to create the biggest buzz in 2018?

Biosimilar availability: 11.0%

Clawbacks or DIR fees: 27.8%

Copay cards for generic drugs: 5.6%

Mergers in healthcare: 50.0%

Outcomes-based agreements: 5.6%

Which of the following best describes how you were affected by the 2017-2018 flu season?

Received the flu vaccine, did not get the flu: 58.33%
Received the flu vaccine, did get the flu: 8.33%
Did not receive the flu vaccine, did not get the flu: 16.67%
Did not receive the flu vaccine, did get the flu: 16.67%

Do you plan to receive the flu vaccine for next flu season?

Yes: 70%
No: 30%

What is the biggest challenge faced by pharmacists today?

Drug shortages: 9.52%

Reimbursement for clinical services: 0%

Staff shortages/long working hours: 23.81%

Managing patient prescription coverage: 4.76%

Reimbursement for prescriptions: 57.14%

Verifying prescription orders/instructions: 0%

None of these: 4.76%

Should physicians be required to participate in mandatory education on opioids as part of ongoing attempts to limit opioid addiction?

Yes: 100%

No: 0%

When authorized generics are introduced to the market without any generic competition, does this help reduce payer cost and improve pharmacy margins?

Yes: 11.2%

No: 0%

Generally yes, but depends on pricing of AG and whether it’s reimbursed as a brand or generic: 44.4%

Generally no, but payer rebates and pharmacy discounts may help: 44.4%